New Open Clinical Trials for Protease Inhibitors, Entry Inhibitors, Abacavir/Lamivudine vs Emtricitabine/Tenofovir, and Vaccine Adherence in Young IDUs
TMC114-C214: Trial of TMC 114 Administered with Low Dose Ritonavir (RTV) in HIV-1-infected Treatment-experienced Patients Condition: HIV Infection TMC114-C209: TMC 114 with Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1-infected Patients with Limited or No Treatment Options Condition: HIV Infections Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E1) Conditions: HIV Infections; Acquired Immunodeficiency Syndrome Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) Conditions: HIV Infections; Acquired Immunodeficiency Syndrome A Dose Ranging Study of GW640385 Boosted with Ritonavir (Rtv) In Comparison To A RTV-Boosted Protease Inhibitor (PI) In HIV-1 Infected PI-Experienced Adults Condition: HIV Infections Abacavir/Lamivudine versus Emtricitabine/Tenofovir Both In Combination with Lopinavir/Ritonavir for the Treatment Of HIV Condition: HIV Infections Observational Study of a Protease Inhibitor (PI)-containing Regimen in Subjects with PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir) Condition: HIV Infections A Randomized Trial of Vaccine Adherence in Young Injection Drug Users Conditions: Adherence; Community Outreach; HIV risk behaviors; Hepatitis A Vaccines; Hepatitis B Vaccines; Hepatitis C; Needle-Exchange Programs;
HIV/AIDS Topics [ A to Z ]
Abacavir Sensitivity Reaction Acquired Drug Resistance Acquired Rectal Fistula Adherence Adolescents African Americans Age/aging AIDS-defining Illnesses AIDS-related Non-Hodgkin's Lymphoma Alcohol Alternative Therapies ALT/AST Anal Intraepithelial Neoplasia (AIN) Anemia / Fatigue Antimycobacterial Prophylaxis Atheroschlerosis Aspergillosis Autoimmune Thyroid Disease Bacteremia Bacterial Infections Bartonella Body Mass Index (BMI) Bone Disorders Boosted Protease Inhibitors Breast-feeding Buffalo Hump (BH) Caesarean section Candidiasis Cancers Cardiovascular Disease CXCR4 Co-receptor CCR5 Co-receptor CD4 T Cell Count/ Percent CD4+ and CD8 in Whole Blood CD8+ T Cell CD8 and CD3 Cells Cerebrospinal Fluid (CSF) Cholesterol / Triglycerides Children and Infants Central Nervous System (CNS) Clinical Trials CMV Retinitis Complementary Alternative Therapies Cosmetic Procedures CYP3A Pathway Cryptococcus Cytomegalovirus Dementia Depression Developing Countries Diabetes Diarrhea / Gastrointestinal Dietary Intake Directly Observed Therapy (DOT) Disease Progression Dosing Drug Abuse Drug Interactions Drug Pricing Drug Resistance Testing Dyslipidemias Elevated bilirubin and Jaundice Elevated Creatinine Level Entry Inhibitors Epstein Barr Virus Epidemiology Eradication (HIV) Ethnicity Experimental Drugs Experimental Vaccine Facial Implants Fat Loss Fat Accumulation Fat Redistribution FDA-Approved Treatments Fixed-dose Combinations (FDC) Flu / Fever Fungal Infections Fusion or Entry Inhibitors GB Virus C (GBC of hepatitis G) Gender Generics Genetics Genotype Resistance Testing Glucose Metabolism / Insulin Resistance Growth Failure Growth Hormone Guidelines Gynecomastia HAART / Mega-HAART Hairy leukoplakia Hepatotoxicity (Liver Toxicity) Hispanic Ethnicity Histoplasmosis HIV Antibody HIV Eradication HIV Prevalence HIV Proviral DNA Testing HIV p24 Antigen HIV-related Adverse Events HIV Replication HIV RNA and HIV bDNA Testing HIV Therapeutics HIV-1 Fitness Assay Hodgkin's Disease Hormone Therapies Hospice Care Human Herpesvirus 8 (HHV-8) Humanpapillomavirus (HPV) Hydroxyurea (HU) Hyperlactatemia Hyperlipidemia Hypersusceptibility Hyperbilirubinemia / Jaundice Hypertension Hypophosphatemia Hypothyroidism Immunotherapy Immune Based Therapy Immunosuppression Immune Restoration Disease Immune Reconstitution Disease (IRD) Immune Reconstitution Inflammatory Syndrome (IRIS) Infants Infective Endocarditis Injection Site Reactions Insulin Resistance Intensification Therapy Injection Drug Users (IDU) Integrase Inhibitors JC Virus Kaposi Sarcoma Kidney Toxicity / Failure Kinetic PCR Lactic Acidosis/Hyperlactatemia Leukoencephalopathy Lipid Abnormalties Lipodystrophy Liver Enzyme Long-term Non Progression Lung Diseases Non-Tuberculosis Lung Diseases Malignancies Mega-HAART Men Who Have Sex with Men (MSM) Meningoencephalitis Microbicides Miscellaneous Mitochondrial Toxicity Morphologic Changes Mortality and Morbidity Mother-to-Child Transmission Multidrug Resistant (MDR) HIV Mutation Resistance Myalgias (muscle aches) Mycobacterium avium Complex Myelopathy Myocardial Infarction (MI) Natural History NAMs (nucleoside-associated resistance mutations) Nausea Neonatal Transmission Nephrotoxicity Neopterin Neurotoxicity Neutropenia Nevirapine-associated Rash Nitazoxanide Nucleic Acid Screening Test Non-AIDS Related Hodgkin's Lymphoma Non-Tuberculosis Lung Diseases Non-Nucleoside Reverse Transcriptase Inhibitors (nNRTIs) Non-occupational Post Eexposure Prophylaxis (NPEP) NNRTI Toxicities and Side Effects Guide Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Nucleotide Reverse Transcriptase Inhibitors (NtRTIs) Nutrition Opportunistic Infections (OIs) Oral OIs/ hairy leukoplakia/ warts Pain Palliative Care Pancreatitis Parasites Pathogenesis Pediatrics Peripheral Neuropathy Perinatal Transmission Pharmacokinetics Pharmacodynamics Pneumonia Pneumocystis carinii pneumonia (PCP) Phenotype Resistance Testing Pharmacokinetics Progressive Multifocal Leukoencephalopathy (PML) Pheumonia Physical Exercise Positron Emission Topography Protease Assay Proteinuria and Elevated Creatinine Level Psychiatric (mental) PML Post Exposure Prophylaxis (PEP) Post-traumatic Stress Disorder (PTSD) Pregnancy Prevention Primary HIV Infection Protease Inhibitors (PIs) / Boosted PIs Protease Inhibitor Toxicities/Side Effects (PDF) Public Policy Quality of Life Race / Ethnicity real-time DNA PCR (RT DNA-PCR) Renal (Kidney) Toxicity / Failure Replication Capacity Tests Resistance Resistance Mutation Resistance Testing Resistance Training Ritonaivr Boosted PIs Safer Sex Salvage Therapies Seroconversion Severe Adverse Drug Reactions Sexual Dysfunction Sexually Transmitted Diseases Side Effects Simplification Regimens/Trials Skin Conditions Smoking Staphylococcus Aureus Steroids Stroke Substance Abuse Suicidal Ideation Survival Super Infection Sustained Virological Response Syphilis Switch Studies TAMs (thymidine analogue mutations) Tat gene Testosterone thrombosis Therapeutic Drug Monitoring (TDM) Therapeutic HIV Vaccines Thyroid Disease Toxicities and Side Effects Toxicities Guides Toxoplasmosis Transmission Transplantation Treatment Failure Treatment Guidelines Treatment Interruptions (TIs) Tuberculosis Undetectable HIV Viral Load Unsafe Sex Vaccines Vaginal HIV Shedding Vertical Transmission of HIV Viral (HIV) Set Point Viral Load (HIV RNA or HIV bDNA) Viral Load Rebound / Increase Virco Antivirogram Virologic Control Virologic Failure Visceral Adiposity Virtual Phenotype Resistance Testing Wasting - HIV White Race / Caucasian Women
